Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Alexion to present long-term Ultomiris and Soliris data in NMOSD at ECTRIMS 2025

Written by | 20 Sep 2025

Alexion, AstraZeneca Rare Disease, will present four abstracts, including one oral presentation, from its leading rare neurology portfolio at the European Committee for Treatment and Research in Multiple… read more.

NICE (UK) recommends danicopan as add on to ravulizumab or eculizumab to treat residual haemolytic anaemia – AstraZeneca

Written by | 8 Nov 2024

NICE (UK): Danicopan (Voydeya) from Alexion/AstraZeneca, is recommended, as an add-on to ravulizumab or eculizumab as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.